病毒載體合作與授權協議（2016-2025）

"病毒載體合作與授權協議" 全面深入分析了全球領先的生物製藥公司簽署的病毒載體協議，並提供前所未有的資訊取得管道。

這份經過全面修訂和更新的報告詳細介紹了2016年至2025年間的病毒載體協議。

本報告深入分析了企業簽訂病毒載體協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，逐步推進到成果的商業化。

本報告涵蓋合作、開發、研究和授權等內容。

本報告提供了自2016年以來公佈的413項病毒載體交易的完整清單。報告還包括可用的財務條款以及相關方披露的實際病毒載體合作交易的線上記錄連結。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告第一章概述了病毒載體交易。

第一章概述了本報告。

第二章概述了自 2016 年以來的病毒載體交易趨勢。

第三章概述了自 2016 年以來主要的病毒載體交易，並依交易總額列出。

第四章提供了病毒載體交易中最活躍的 25 家公司的完整列表，並附有簡要概述，隨後提供了病毒載體交易的完整列表以及公開可獲取的合同文件。

第五章對自 2016 年 1 月以來已完成和已宣布的、且有公開可獲取合約文件的病毒載體交易進行了全面深入的審查。

第六章對自2016年1月以來簽署和公佈的病毒載體合作協議進行了全面深入的回顧。本章以具體的病毒載體技術類型進行組織。

報告還包含大量表格和圖表，展示了自2016年以來病毒載體交易的趨勢和活動。

此外，我們還提供了一個全面的合約目錄，依公司名稱（A-Z）、合約類型和治療標靶進行分類。每個合約標題都透過網路連結指向線上合約記錄，並在可用的情況下指向合約文件，方便用戶根據需要輕鬆存取每個合約文件。

主要優勢

"病毒載體合作與授權協議" 提供讀者以下主要優勢：

• 了解自 2016 年以來的交易趨勢
• 瀏覽病毒載體合作與授權協議
• 基準分析 - 確定交易市場價值
• 財務條款 - 預付款、里程碑付款、特許權使用費
• 依公司（A-Z）、協議類型和治療領域分類的合約目錄
• 以價值排名的主要交易
• 最活躍的交易撮合者
• 確定每筆交易的資產和條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

範圍

• "病毒載體合作與授權協議" "病毒載體合作與授權協議" 報告旨在幫助讀者深入了解全球生物製藥公司之間病毒載體相關協議的趨勢和結構。

"病毒載體合作與授權協議" 包含以下內容：

• 生物製藥產業病毒載體交易趨勢
• 製藥和生物技術公司病毒載體合約記錄目錄
• 依價值排名的主要病毒載體合約
• 最活躍的病毒載體授權協議提供者
• "病毒載體合作與許可協議" 提供對現有合約記錄的全面訪問，包括合約文件（如有）。

分析合約有助於對以下內容進行盡職調查：

• 合約明確授予或選擇哪些權利？
• 合約實際授予合作夥伴哪些權利？
• 授予了哪些獨家權利？
• 交易的付款結構是什麼？
• 銷售和付款如何審計？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 智慧財產權（IPR）如何處理歸屬於誰？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更會發生什麼事？
• 如何約定轉讓許可和分包條款？
• 貴公司要求使用哪些標準條款？
• 哪些標準條款會因交易對手和交易類型而異？
• 貴公司必須在哪個司法管轄區內執行其合約？

目錄

摘要整理

第一章：引言

第二章：病毒載體交易趨勢

• 引言
• 歷年病毒載體交易狀況
• 最活躍的病毒載體交易商
• 依交易類型劃分的病毒載體交易
• 依治療領域劃分的病毒載體交易
• 依行業劃分的病毒載體交易
• 病毒載體交易條款
  • 病毒載體交易總額
  • 病毒載體交易預付款
  • 病毒載體交易里程碑付款
  • 病毒載體特許權使用費率

第三章 - 主要病毒載體交易

• 引言
• 以價值排名的頂級病毒載體交易

第四章 - 最活躍的病毒載體經銷商

• 引言
• 最活躍的病毒載體經銷商
• 最活躍的病毒載體經銷商公司簡介

第五章 - 病毒載體合約交易目錄

• 引言
• 病毒載體合約交易目錄

第六章 - 依技術類型劃分的病毒載體交易

• 交易目錄
• 依公司劃分的病毒載體交易目錄 (AZ)
• 依交易類型劃分的病毒載體交易目錄
• 依治療領域劃分的病毒載體交易目錄
• 交易類型定義
• 關於本研究公司
• 當前合作夥伴關係
• 當前協議
• 當前合作夥伴關係近期報告標題

Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of viral vector deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter viral vector deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 413 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of viral vector dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral vector dealmaking since 2016.

Chapter 3 provides an overview of the leading viral vector deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of viral vector deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in viral vector deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse viral vector collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Viral Vector Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of viral vector trends and structure of deals entered into by leading biopharma companies worldwide.

Viral Vector Collaboration and Licensing Deals includes:

• Trends in viral vector dealmaking in the biopharma industry
• Directory of viral vector deal records covering pharmaceutical and biotechnology
• The leading viral vector deals by value
• Most active viral vector licensing dealmakers
• Viral Vector Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral vector dealmaking

• 2.1. Introduction
• 2.2. Viral vector deals over the years
• 2.3. Most active viral vector dealmakers
• 2.4. Viral vector deals by deal type
• 2.5. Viral vector deals by therapy area
• 2.6. Viral vector deals by industry sector
• 2.7. Deal terms for viral vector deals
  • 2.7.1 Viral vector deals headline values
  • 2.7.2 Viral vector deal upfront payments
  • 2.7.3 Viral vector deal milestone payments
  • 2.7.4 Viral vector royalty rates

Chapter 3 - Leading viral vector deals

• 3.1. Introduction
• 3.2. Top viral vector deals by value

Chapter 4 - Most active viral vector dealmakers

• 4.1. Introduction
• 4.2. Most active viral vector dealmakers
• 4.3. Most active viral vector deals company profiles

Chapter 5 - Viral vector contracts dealmaking directory

• 5.1. Introduction
• 5.2. Viral vector contracts dealmaking directory

Chapter 6 - Viral vector dealmaking by technology type

• Deal directory
• Deal directory - Viral vector deals by company A-Z
• Deal directory - Viral vector deals by deal type
• Deal directory - Viral vector deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Viral vector deals since 2016
• Figure 2: Active viral vector dealmaking activity - 2016 - 2025
• Figure 3: Viral vector deals by deal type since 2016
• Figure 4: Viral vector deals by therapy area since 2016
• Figure 5: Viral vector deals by industry sector since 2016
• Figure 6: Viral vector deals with a headline value
• Figure 7: Viral vector deals with an upfront value
• Figure 8: Viral vector deals with a milestone value
• Figure 9: Viral vector deals with a royalty rate value
• Figure 10: Top viral vector deals by value since 2016
• Figure 11: Most active viral vector dealmakers 2016 - 2025
• Figure 12: Viral vector deals by technology type since 2016